AbbVie (ABBV) reported $61.2B in revenue for fiscal 2025, +8.6% year on year. That ranks #83 by revenue among 2853 SEC filers and #15 in Healthcare. Net income was $4.2B, a net margin of 6.9%. Revenue has grown 10.1% a year on average since 2016 ($25.6B then). The fiscal 2025 balance sheet shows $134B in total assets, $5.2B in cash and $64.5B in long-term debt.
Key figures
| Key figures | FY2025 | YoY | Source |
|---|---|---|---|
| RevenueRevenueFromContractWithCustomerExcludingAssessedTax | $61.2B | +8.6% | FY20252025-12-31 |
| Gross profit | Not reported | — | |
| Operating incomeOperatingIncomeLoss | $15.1B | +65.0% | FY20252025-12-31 |
| Net incomeNetIncomeLoss | $4.2B | −1.2% | FY20252025-12-31 |
| Operating cash flowNetCashProvidedByUsedInOperatingActivities | $19.0B | +1.2% | FY20252025-12-31 |
| Capital expenditurePaymentsToAcquirePropertyPlantAndEquipment | $1.2B | +24.6% | FY20252025-12-31 |
| Total assetsAssets | $134B | −0.9% | FY20252025-12-31 |
| Shareholders' equityStockholdersEquity | −$3.3B | −$6.6B | FY20252025-12-31 |
| CashCashAndCashEquivalentsAtCarryingValue | $5.2B | −5.3% | FY20252025-12-31 |
| Long-term debtLongTermDebt | $64.5B | −3.5% | FY20252025-12-31 |
Revenue is total net sales for the fiscal year, taken from each company's own annual filing.
Reported since the last full year
Three-month figures this company has filed since FY2025. A quarter is not comparable with a full year, and these figures are used nowhere else on the site: not in any ranking, not in comparisons, not in the download.
| Quarter | Revenue | Net income | Source |
|---|---|---|---|
| Q1 20262026-03-31 | $15.0B | $695M | Open → |
| Q2 20262026-06-30 | $17.0B | $3.6B | Open → |
Only periods that end on a calendar quarter appear here. A company whose fiscal year ends in June files on a different calendar, so it has no row.
Where this sits in its sector
Each bar is the spread of the whole sector: the box covers the middle half of companies, the line inside it the median, and the triangle this company. The axis is clipped at the 5th and 95th percentile so a single outlier does not flatten it.
| Where this sits in its sector | FY2025 | Position in sector |
|---|---|---|
| Net marginRank 75 of 161 companies compared | 6.9% | |
| Operating marginRank 25 of 160 companies compared | 24.6% | |
| R&D as share of revenueRank 36 of 102 companies compared | 14.9% | |
| Cash as share of revenueRank 101 of 160 companies compared | 8.5% |
All four are ratios derived from two reported lines, not single filing items. Peer group: companies in the same sector with revenue of $1bn or more; loss-making companies are included.
Profile
- Legal name
- AbbVie Inc.
- Ticker
- ABBV
- Exchange
- NYSE
- SIC classification
- Pharmaceutical Preparations (2834)
- Fiscal year end
- 12-31
- CIK
- 0001551152
Filings
- 10-QAug 3, 2026Open filing →
- 10-QMay 8, 2026Open filing →
- 10-KFeb 20, 2026Open filing →
Similar in size, same sector
| Company | Revenue | Net income |
|---|---|---|
| Eli LillyLLY | $65.2B | $20.6B |
| MerckMRK | $65.0B | $18.3B |
| PfizerPFE | $62.6B | $7.8B |
| AbbVieABBV | $61.2B | $4.2B |
| AstraZenecaAZN | $58.7B | $10.2B |
| Bristol Myers SquibbBMY | $48.2B | $7.1B |
| Novo Nordisk A SNVO | $46.8B | $15.5B |
AbbVie compared withAstraZenecaPfizer
Cite this page
Ready-made references for the figures on this page, as published on September 25, 2026.
Wikipedia
{{cite web |title=AbbVie — Key figures |url=https://companiesranked.com/en/company/abbvie |website=CompaniesRanked |date=2026-09-25 |language=en}}APA 7
CompaniesRanked. (September 25, 2026). AbbVie — Key figures. CompaniesRanked. https://companiesranked.com/en/company/abbvieBibTeX
@misc{companiesranked-en-company-abbvie-2026,
author = {{CompaniesRanked}},
title = {{AbbVie — Key figures}},
year = {2026},
howpublished = {\url{https://companiesranked.com/en/company/abbvie}},
note = {Compiled from SEC EDGAR XBRL filings; data as of 2026-09-25},
urldate = {2026-09-25}
}The filing itself
The numbers above are read from this document: 10-K · 0001551152-26-000008 · February 20, 2026
{{cite web |title=AbbVie — Key figures — 10-K (0001551152-26-000008) |url=https://www.sec.gov/Archives/edgar/data/1551152/000155115226000008/abbv-20251231.htm |website=SEC EDGAR |publisher=U.S. Securities and Exchange Commission |date=2026-02-20}}The figures are rebuilt with every data refresh, so the reference carries the publication date. Add your own access date if your style requires one.